Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRACkER trial of triple therapy versus dual bronchodilator therapy in COPD patients with asthma characteristics
NL-OMON54789Phase 4Active, not recruiting
- Sponsor
- General Practitioners Research Institute
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of beclometasone dipropionate/formoterol fumarate/glycopyrronium and long-acting beta2-agonist + long-acting muscarinic antagonist in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by General Practitioners Research Institute. Started Sep 2020; status: active, not recruiting.
02
Drugs
beclometasone dipropionate/formoterol fumarate/glycopyrroniumlong-acting beta2-agonist + long-acting muscarinic antagonist
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON54789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54789.